Efficacy of Pertuzumab

Pertuzumab was studied in a major study involving 808 adults with previously untreated HER2-positive metastatic breast cancer. The effects of pertuzumab were compared to a placebo (dummy treatment) when given with other cancer drugs (trastuzumab and docetaxel). Patients were treated until their disease worsened or the side effects of treatment became unmanageable, and those who received pertuzumab lived for 18.5 months without disease progression.

Pertuzumab was also studied in two major studies involving a total of642 patients with early-stage breast cancer who underwent surgery. In these studies, pertuzumab was given with trastuzumab or chemotherapy or both. These studies looked at how many patients responded to treatment (i.e., those who had no cancer cells in their breasts after surgery). In the first study, 46% of patients who received pertuzumab plus trastuzumab and docetaxel responded to treatment, and in the second study, where pertuzumab was combined with trastuzumab and chemotherapy, responses ranged from 57% to 66%.

Pertuzumab is a strictly controlled drug. The original drug has been marketed in China and has entered the ranks of medical insurance, but it is only reimbursed for patients who meet the indications. The price of each box may be more than more than 5,000 yuan, and the price of the Hong Kong version may be more than 20,000 yuan (the price may fluctuate due to exchange rates). The price of each box of the European version of Pertuzumab's original drug marketed overseas may be more than 10,000 yuan, and the price of each box of the Turkish version may be more than 6,000 yuan (the price may fluctuate due to exchange rates). The ingredients of the domestic and foreign original drugs are basically the same, and there are currently no generic versions of Pertuzumab on the market.